Global Retinal Gene Therapy Market Overview:
Global Retinal Gene Therapy Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Retinal Gene Therapy Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Retinal Gene Therapy involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Retinal Gene Therapy Market:
The Retinal Gene Therapy Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Retinal Gene Therapy Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Retinal Gene Therapy Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Retinal Gene Therapy market has been segmented into:
Leber Congenital Amaurosis
Retinitis Pigmentosa
Stargardt Disease
Choroideremia
By Application, Retinal Gene Therapy market has been segmented into:
Adeno-Associated Virus
Lentivirus
Messenger RNA
DNA
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Retinal Gene Therapy market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Retinal Gene Therapy market.
Top Key Players Covered in Retinal Gene Therapy market are:
Astellas Pharma
MeiraGTx
Ocugen
GenSight Biologics
AbbVie
Roche
Dohmen Life Science Services
MediGene
Rising Pharmaceuticals
Bayer
Spark Therapeutics
Novartis
Applied Genetic Technologies Corporation
Sobi
Perlita Therapeutics
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Retinal Gene Therapy Market Type
4.1 Retinal Gene Therapy Market Snapshot and Growth Engine
4.2 Retinal Gene Therapy Market Overview
4.3 Leber Congenital Amaurosis
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Leber Congenital Amaurosis: Geographic Segmentation Analysis
4.4 Retinitis Pigmentosa
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Retinitis Pigmentosa: Geographic Segmentation Analysis
4.5 Stargardt Disease
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Stargardt Disease: Geographic Segmentation Analysis
4.6 Choroideremia
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Choroideremia: Geographic Segmentation Analysis
Chapter 5: Retinal Gene Therapy Market Application
5.1 Retinal Gene Therapy Market Snapshot and Growth Engine
5.2 Retinal Gene Therapy Market Overview
5.3 Adeno-Associated Virus
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Adeno-Associated Virus: Geographic Segmentation Analysis
5.4 Lentivirus
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Lentivirus: Geographic Segmentation Analysis
5.5 Messenger RNA
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Messenger RNA: Geographic Segmentation Analysis
5.6 DNA
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 DNA: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Retinal Gene Therapy Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ASTELLAS PHARMA
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 MEIRAGTX
6.4 OCUGEN
6.5 GENSIGHT BIOLOGICS
6.6 ABBVIE
6.7 ROCHE
6.8 DOHMEN LIFE SCIENCE SERVICES
6.9 MEDIGENE
6.10 RISING PHARMACEUTICALS
6.11 BAYER
6.12 SPARK THERAPEUTICS
6.13 NOVARTIS
6.14 APPLIED GENETIC TECHNOLOGIES CORPORATION
6.15 SOBI
6.16 PERLITA THERAPEUTICS
Chapter 7: Global Retinal Gene Therapy Market By Region
7.1 Overview
7.2. North America Retinal Gene Therapy Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Leber Congenital Amaurosis
7.2.2.2 Retinitis Pigmentosa
7.2.2.3 Stargardt Disease
7.2.2.4 Choroideremia
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Adeno-Associated Virus
7.2.3.2 Lentivirus
7.2.3.3 Messenger RNA
7.2.3.4 DNA
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Retinal Gene Therapy Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Leber Congenital Amaurosis
7.3.2.2 Retinitis Pigmentosa
7.3.2.3 Stargardt Disease
7.3.2.4 Choroideremia
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Adeno-Associated Virus
7.3.3.2 Lentivirus
7.3.3.3 Messenger RNA
7.3.3.4 DNA
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Retinal Gene Therapy Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Leber Congenital Amaurosis
7.4.2.2 Retinitis Pigmentosa
7.4.2.3 Stargardt Disease
7.4.2.4 Choroideremia
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Adeno-Associated Virus
7.4.3.2 Lentivirus
7.4.3.3 Messenger RNA
7.4.3.4 DNA
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Retinal Gene Therapy Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Leber Congenital Amaurosis
7.5.2.2 Retinitis Pigmentosa
7.5.2.3 Stargardt Disease
7.5.2.4 Choroideremia
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Adeno-Associated Virus
7.5.3.2 Lentivirus
7.5.3.3 Messenger RNA
7.5.3.4 DNA
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Retinal Gene Therapy Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Leber Congenital Amaurosis
7.6.2.2 Retinitis Pigmentosa
7.6.2.3 Stargardt Disease
7.6.2.4 Choroideremia
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Adeno-Associated Virus
7.6.3.2 Lentivirus
7.6.3.3 Messenger RNA
7.6.3.4 DNA
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Retinal Gene Therapy Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Leber Congenital Amaurosis
7.7.2.2 Retinitis Pigmentosa
7.7.2.3 Stargardt Disease
7.7.2.4 Choroideremia
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Adeno-Associated Virus
7.7.3.2 Lentivirus
7.7.3.3 Messenger RNA
7.7.3.4 DNA
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Retinal Gene Therapy Scope:
|
Report Data
|
Retinal Gene Therapy Market
|
|
Retinal Gene Therapy Market Size in 2025
|
USD XX million
|
|
Retinal Gene Therapy CAGR 2025 - 2032
|
XX%
|
|
Retinal Gene Therapy Base Year
|
2024
|
|
Retinal Gene Therapy Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Astellas Pharma, MeiraGTx, Ocugen, GenSight Biologics, AbbVie, Roche, Dohmen Life Science Services, MediGene, Rising Pharmaceuticals, Bayer, Spark Therapeutics, Novartis, Applied Genetic Technologies Corporation, Sobi, Perlita Therapeutics.
|
|
Key Segments
|
By Type
Leber Congenital Amaurosis
Retinitis Pigmentosa
Stargardt Disease
Choroideremia
By Applications
Adeno-Associated Virus
Lentivirus
Messenger RNA
DNA
|
